A new combination therapy has shown promise in extending survival for patients with a specific type of lung cancer in As...
India-based Zydus Lifesciences (including its subsidiaries and affiliates), has signed an exclusive development, licensi...
Pfizer’s NURTEC® (rimegepant), an orally disintegrating tablet for both the acute treatment of migraine is now...
Shanghai Junshi Biosciences Co. has collaborated with Indian pharmaceutical firm Dr. Reddy’s Laboratories to devel...
GSK Singapore announced that Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5...
Japan headquatered Takeda's EXKIVITY (mobocertinib) has been approved by the National Medical Products Administration (N...
The current diabetic neuropathic pain treatment paradigm includes many established analgesics that provide sym...
A major clinical trial of an antibody treatment may soon pave the way for improved treatment of Alzheimer’s diseas...
German firm Heidelberg Pharma AG and Huadong Medicine in China have entered into a strategic partner...
Japanese firms Takeda Pharmaceutical Company and JCR Pharmaceuticals have announced a geographically-focused exclusive c...
South Korea-based Samsung Bioepis has announced that the US Food and Drug Administration (FDA) has approved BYOOVIZ...
US-based Mirum Pharmaceuticals, Inc. and Japanese firm Takeda Pharmaceutical have entered into an exclusive licensing ag...
Australian patients with an aggressive form of lung cancer (metastatic Small Cell Lung Cancer) can now access a new...
Eli Lilly Japan and Daiichi Sankyo Company have concluded an agreement on commercialisation collaboration in Japan for t...
Japan-based Eisai and FUJI YAKUHIN have inked a license agreement concerning dotinurad (generic name), a treatment for h...
Singapore-based Menarini Asia-Pacific Holdings, a part of the leading Italian global biopharmaceutical company Menarini ...
The UK National Institute for Health and Care Excellence (NICE) has published new draft guidance which recommends Eli Li...
U.S. Food and Drug Administration (FDA) has approved a combination therapy from Eisai and Merck (MSD) namely,&...
Yuyu Pharma and Novartis Korea have entered into an agreement in which Yuyu will have exclusive distribution rights for ...
Medtronic, (headquartered in Dublin, Ireland), the global leader in medical technology, announced U.S. Food and Dru...
Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the world's largest Italian biopharmaceutical comp...
Sinovac Biotech, a leading provider of biopharmaceutical products in China, has received a drug registration approval fr...
In conjunction with the IAS Conference on HIV Science, Germany's Frontier Biotechnologies has announced positive top-lin...
Eisai's Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofic...
The European Commission has granted marketing authorization for Jardiance®(empagliflozin) as a treatment for adults ...
Japanese scientists are scanning the possibility of using an anti-malarial drug called mefloquine....
eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and ...
Vectura Group has signed an agreement with Australia-based Incannex Healthcare to provide pre-clinical development servi...
Rancho Santa Fe Bio, Inc. (RSF Bio), a San Diego, California-based clinical-stage cardiovascular platform company, annou...
Merck has signed a collaboration agreement with Janssen Pharmaceuticals NV around the commercialization of INVOKANA...
Peptron, Inc., a South Korea-based biotech company, and Qilu Pharmaceutical, a China-based pharmaceutical company f...
The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments ...
SK Biopharmaceuticals, Co., Ltd., a global innovative pharmaceutical company, announced that cenobamate received marketi...
Sydney-based Kazia Therapeutics Limited, an oncology-focused drug development company announced that it has entered into...
Astellas Pharma Inc. announced on March 31, 2021, that XOSPATA® (generic name: gilteritinib) is now available for pr...
Eisai Co., Ltd. announced on March 30, 2021 that the European Medicines Agency (EMA) has confirmed it has acce...
EirGenix, Inc. announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimi...
Japanese firm Eisai Co., Ltd. as part of its strategic investment to realize its medium-term management plan, EWAY ...
Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-hou...
Eisai Co., Ltd. has announced that Eisai Korea Inc., (Eisai's subsidiary in South Korea) has launched the Parkinson's di...
Standigm Inc, an artificial intelligence (AI)-based drug discovery company and SK Chemicals Co, Ltd, a life science and ...
Chugai Pharmaceutical Co., Ltd. announced that Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obta...
AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chro...
Gilead Sciences K.K. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Luc Hermans) and Eisai Co.,...
Singapore's Health Sciences Authority (HSA) recently approved an immunotherapy regimen (Tecentriq + Avastin) t...
A NEW therapy to treat advanced gastrointestinal stromal tumours (GIST) will be available to patients in Australia,...
TaiGen Biotechnology Company, Limited (TaiGen) in Taiwan has announced that U.S. Food and Drug Administration (FDA) has ...
Microcrystal electron diffraction (MicroED) is a new crystal structure determination technique for small molecules. It o...
Japanese firm FUJIFILM Toyama Chemical Co., Ltd. has announced that the company filed an Application for Partial Changes...
The Indian state, Maharashtra has become the first to fix the price of remdesivir at INR2,360 (US$32.17), which is 16% m...
Eisai Co., Ltd. on 16 Oct 2020 announced that the supplementary new drug applications for its in-house discovered and de...
